CD79A and COVID-19: Interestingly, we identified that individuals immunized with BNT62b2 vaccine who displayed higher anti-S IgA and IgG antibody levels exhibited a lower incidence of COVID-19 after vaccination, compared to those immunized with adenovirus vector-based vaccines.